| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2007;38:2563.)
© 2007 American Heart Association, Inc.
Original Contributions |
From the Departments of Anesthesia and Perioperative Care (C.Z.L., Z.X., Y.Z., G.-Y.Y., W.L.Y.), Neurological Surgery (G.-Y.Y., W.L.Y.), and Neurology (W.L.Y.), Center for Cerebrovascular Research, University of California, San Francisco, San Francisco, Calif.
Correspondence to William L. Young, MD, University of California, San Francisco, Department of Anesthesia and Perioperative Care, 1001 Potrero Avenue, Room 3C-38, San Francisco, CA 94110. E-mail ccr{at}anesthesia.ucsf.edu
Background and Purpose— Human brain arteriovenous malformation tissue displays increased levels of vascular endothelial growth factor (VEGF) as well as matrix metalloproteinase (MMP)-9, a tissue protease associated with various intracerebral hemorrhage (ICH). We hypothesized that increased MMP-9 was associated with ICH induced by vascular endothelial growth factor hyperstimulation and that this effect could be attenuated by nonspecific MMP inhibition.
Methods— We used a mouse model with adenoviral vector-mediated vascular endothelial growth factor transduction in the brain. The association of MMP-9 expression and the brain tissue hemoglobin levels, an index of ICH, after stereotactic injection of adenoviral vector-mediated vascular endothelial growth factor into caudate putamen was assessed. A dose–response study with adenoviral vector-mediated vascular endothelial growth factor and a time course study at both 24 and 48 hours postinjection were performed. Effects of minocycline, a nonspecific MMP inhibitor, and pyrrolidine dithiocarbamate, an upstream regulator of MMPs, on MMP-9 activity and thereby the degree of ICH were also tested.
Results— Adenoviral vector-mediated vascular endothelial growth factor at the higher dose and at 48 hours induced MMP-9 levels 6-fold (n=6, P=0.02) and increased brain tissue hemoglobin (43.4±11.5 versus 30.3±4.1 µg/mg, n=6, P=0.003) compared with the adenoviral vector control. Immnunostaining was positive for MMP-9 around the cerebral vessels and the hemorrhagic areas. Minocycline and pyrrolidine dithiocarbamate administration suppressed vascular endothelial growth factor-induced MMP-9 activity (n=6, P=0.003 and P=0.01, respectively) and the associated increases in hemoglobin levels (n=5–6, P=0.001 and P=0.02, respectively).
Conclusions— Vascular endothelial growth factor-induced ICH is associated with increased MMP-9 expression. Suppression of MMP-9 by minocycline or pyrrolidine dithiocarbamate attenuated ICH, suggesting the therapeutic potential of MMP inhibitors in cerebral vascular rupture.
Key Words: intracerebral hemorrhage matrix metalloproteinase minocycline pyrrolidine dithiocarbamate vascular endothelial growth factor
This article has been cited by other articles:
![]() |
C. Z. Lee, Z. Xue, Q. Hao, G.-Y. Yang, and W. L. Young Nitric Oxide in Vascular Endothelial Growth Factor-Induced Focal Angiogenesis and Matrix Metalloproteinase-9 Activity in the Mouse Brain Stroke, August 1, 2009; 40(8): 2879 - 2881. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kim, L. Pawlikowska, Y. Chen, H. Su, G.-Y. Yang, and W. L. Young Brain Arteriovenous Malformation Biology Relevant to Hemorrhage and Implication for Therapeutic Development Stroke, March 1, 2009; 40(3_suppl_1): S95 - S97. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Hao, H. Su, D. A. Marchuk, R. Rola, Y. Wang, W. Liu, W. L. Young, and G.-Y. Yang Increased tissue perfusion promotes capillary dysplasia in the ALK1-deficient mouse brain following VEGF stimulation Am J Physiol Heart Circ Physiol, December 1, 2008; 295(6): H2250 - H2256. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Murphy, M. T. Y. Lam, X. Wu, T. N. Kim, S. M. Vartanian, A. W. Bollen, T. R. Carlson, and R. A. Wang Endothelial Notch4 signaling induces hallmarks of brain arteriovenous malformations in mice PNAS, August 5, 2008; 105(31): 10901 - 10906. [Abstract] [Full Text] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |